PACB Investors Have Opportunity to Join Pacific Biosciences of California, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. PacBio preannounced poor top-line results for the first quarter of 2024 on April 16, 2024. The Company also announced a reduction in its full-year guidance for 2024 and revised its long-term guidance for fiscal year 2026. The Company blamed its shortfalls on “an increasing number of customers delay instrument purchases and we experienced some unexpected softness in consumable shipments.” Analysts were alarmed by the Company’s performance, indicating it was “far worse than we expected.”
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Contacts
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com
